Key Highlights

  • A 16.55% indicated pre-market advance lifts the price to USD 0.50 on November 18, 2026, measured against a calculated prior close of USD 0.4290.
  • Third quarter 2026 sales near USD 48,000 came with a net Deficit of around USD 3.2 million and cash of roughly USD 11.5 million.
  • A calculated Market Value of USD 9.8 million, built from 19.67 million shares at USD 0.50, places the company firmly among nano-caps.
  • A grant disbursement of USD 851,796, disclosed on November 16, 2026, belongs to an arrangement worth up to about USD 10.7 million.

Pre-Market Price Move: Dare Bioscience (NASDAQ:DARE) Advances Without a Fresh Release

Dare Bioscience stock is priced at an indicated USD 0.50 before the November 18, 2026 session opens, equal to a 16.55% advance. Working backwards with a 1.1655 divisor yields a calculated prior close of USD 0.4290, which means the per-share gain is USD 0.0710. Multiplying 19.67 million shares by USD 0.50 produces a calculated market value of roughly USD 9.8 million, a yardstick worth keeping in mind when judging this rise for Dare Bioscience.

The Rationale: Post-Results Momentum and Grant Funding at Dare Bioscience

Nothing dated November 18, 2026 appeared in the coverage reviewed, so this advance seems to carry forward the November 17, 2026 trading that came after the quarterly update. Dare Bioscience released its third quarter 2026 numbers on November 16, 2026: sales near USD 48,000, a loss of around USD 3.2 million, and roughly USD 11.5 million in cash, per the summary from the earnings call. Dividing that cash by the loss pace implies a calculated runway of 3.6 quarters. On the same date a grant disbursement of USD 851,796 arrived, the penultimate expected installment of a deal whose ceiling is near USD 10.7 million, while earlier payments were roughly USD 5.4 million in 2024 and USD 3.6 million in November 2025.

Revenue Trend, Dilution Pressure and Listing Risk for Dare Bioscience

Fiscal 2025 Top Line came to USD 1.03 million, versus USD 9,784 in the prior year, and the loss totalled roughly USD 13.40 million. The Trailing Twelve Months show USD 1.37 million of sales, a net deficit of USD 10.99 million and USD 0.78 lost per share. DARE to PLAY is a sildenafil-based topical cream aimed at women and filled through a Section 503B outsourcing site, and the agency could alter the compounding framework that governs it. Going-concern and Nasdaq listing-compliance hazards also appear in forward-looking remarks, so at a calculated USD 9.8 million valuation and a share price below USD 1.00, Dare Bioscience faces dilution and thin trading exposure.

Where Things Stand

The indicated pre-market quote for Dare Bioscience is USD 0.50 ahead of the November 18, 2026 open, implying a rise of 16.55% over a calculated base of USD 0.4290. No scheduled event for the day was identified as the trigger. Sales of about USD 48,000, a loss near USD 3.2 million, roughly USD 11.5 million of cash and a USD 851,796 grant receipt were all dated November 16. The calculated USD 9.8 million Capitalisation keeps dilution and nano-cap swings front of mind. Pre-market readings can change, and this piece is informational rather than Investment advice.